These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4170 related articles for article (PubMed ID: 25075903)
41. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Larson MH; Gilbert LA; Wang X; Lim WA; Weissman JS; Qi LS Nat Protoc; 2013 Nov; 8(11):2180-96. PubMed ID: 24136345 [TBL] [Abstract][Full Text] [Related]
42. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species. Wang P mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980 [No Abstract] [Full Text] [Related]
44. CRISPR-Cas9 technology: applications and human disease modelling. Torres-Ruiz R; Rodriguez-Perales S Brief Funct Genomics; 2017 Jan; 16(1):4-12. PubMed ID: 27345434 [TBL] [Abstract][Full Text] [Related]
45. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576 [TBL] [Abstract][Full Text] [Related]
46. Generation of eGFP and Cre knockin rats by CRISPR/Cas9. Ma Y; Ma J; Zhang X; Chen W; Yu L; Lu Y; Bai L; Shen B; Huang X; Zhang L FEBS J; 2014 Sep; 281(17):3779-90. PubMed ID: 25039742 [TBL] [Abstract][Full Text] [Related]
47. More specific CRISPR editing. de Souza N Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782 [No Abstract] [Full Text] [Related]
48. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders. Wan T; Ping Y Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111 [TBL] [Abstract][Full Text] [Related]
49. Viral Delivery Systems for CRISPR. Xu CL; Ruan MZC; Mahajan VB; Tsang SH Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179 [TBL] [Abstract][Full Text] [Related]
50. An Introduction to CRISPR Technology for Genome Activation and Repression in Mammalian Cells. Du D; Qi LS Cold Spring Harb Protoc; 2016 Jan; 2016(1):pdb.top086835. PubMed ID: 26729914 [TBL] [Abstract][Full Text] [Related]
51. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? Taylor J; Woodcock S J Biomol Screen; 2015 Sep; 20(8):1040-51. PubMed ID: 26048892 [TBL] [Abstract][Full Text] [Related]
52. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727 [TBL] [Abstract][Full Text] [Related]
53. Genome modification by CRISPR/Cas9. Ma Y; Zhang L; Huang X FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507 [TBL] [Abstract][Full Text] [Related]